• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2007 Fiscal Year Final Research Report Summary

Research of prevention of type 1 diabetes by thiazolidine derivative.

Research Project

Project/Area Number 17590931
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Metabolomics
Research InstitutionKobe University

Principal Investigator

NAGATA Masao  Kobe University, Graduate School of Medicine, Associate Professor (70294220)

Co-Investigator(Kenkyū-buntansha) YOKONO Koichi  Kobe University, Graduate School of Medicine, Professor (50144580)
MORIYAMA Hiroaki  Kobe University, Graduate School of Medicine, COE Research Fellow (70372646)
NAKAMURA Masato  Kyoto Prefectual University of Medicine, 大学院・医学系研究科, Associate Professor (40227921)
TAKAHASHI Kazuma  Iwate Medical University, 医学部, Lecturer (60292215)
KAWAMURA Tomoyuki  Osaka City University, Graduate School of Medicine, Assistant Professor (60271186)
Project Period (FY) 2005 – 2007
KeywordsType 1 diabetes / Thiazolidine derivative / Pioglitazone / Dendritic cells / NOD mouse
Research Abstract

1. Prevention of type 1 diabetes by pioglitazone in NOD mice
Oral administration of pioglitazone prevented overt diabetes in female NOD mice not only from 4 weeks of age but also from 10 weeks of age when most of pancreas already showed intra-islet cellar infiltration. Transfer experiments using spleen cells to NOD-scid mice revealed that effector activity was decreased, whereas immuno-regulatory activity was not enhanced by pioglitazone administration_ Flow cytometric analysis showed that CD25^+ CD4^+ T cells were not increased but NKT cells were increased by pioglitazone. Cell surface of dendritic cells showed the increased expression of CD80, co-stimulatory molecule B7-1, and CD1d. These results suggested that the characteristics of dendritic cells were changed by pioglitazone and enhanced NKT cells, leading the autoimmune response to pancreatic β cells. Our study revealed that modification of dendritic cells is one of powerful strategy to prevent type 1 diabetes.
2. Prevention of the progression of pancreatic β cell destruction in human type 1 diabetes
To evaluate the effect of pioglitazone on human type 1 diabetes, we administered pioglitazone with intensive insulin therapy to acute type 1 diabetes. During 2 years follow up, three patients with pioglitazone 30mg/day showed progressive decrease of serum C-peptide level and required much more dose of insulin to control blood sugar. Furthermore, one slowly progressive patient became keto-acidosis after 23 months administration of pioglitazone. These results suggests that at least ordinal dose of pioglitazone cannot inhibit progression of β cell destruction in human type 1 diabetes.

  • Research Products

    (13 results)

All 2008 2007 2006 Other

All Journal Article (10 results) (of which Peer Reviewed: 5 results) Presentation (3 results)

  • [Journal Article] Immunological aspects of 'fulminant type 1 diabetes'2008

    • Author(s)
      Nagata M, et. al.
    • Journal Title

      Diabetes Res Clin Pract.

      Pages: S99-S103

    • Description
      「研究成果報告書概要(和文)」より
    • Peer Reviewed
  • [Journal Article] Prevention of recurrent but not spontaneous autoimmuno diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules.2008

    • Author(s)
      Sakata M, et. al.
    • Journal Title

      Diabetes Res Clin Pract. 80(3)

      Pages: 352-9

    • Description
      「研究成果報告書概要(和文)」より
    • Peer Reviewed
  • [Journal Article] Low-dose warfarin functions as an immunomodulator to prevent cyclo phosphamide-induced NOD diabetes.2008

    • Author(s)
      Kurohara M, et. al.
    • Journal Title

      Kobe J. Med. Sci. (印刷中)(In press)

    • Description
      「研究成果報告書概要(和文)」より
    • Peer Reviewed
  • [Journal Article] Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules2008

    • Author(s)
      Sakata, M, Yasuda, H, Moriyama, H, Yamada, K, Kotani, R, Kurohara, M, Okumachi, Y, Kishi, M, Arai, T, Hara, K, Hamada, H, Yokono, K, Nagata, M
    • Journal Title

      Diabetes Res Clin Pract 80(3)

      Pages: 352-9

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Modification of the Rb-binding Domain of Replication-Competent Adenovirus Vector Enhances Cytotoxicity Against Human Esophageal Cancers via NF-kB Activity2007

    • Author(s)
      Yamada K, et. al.
    • Journal Title

      Hum Gene Ther. 18(5)

      Pages: 389-400

    • Description
      「研究成果報告書概要(和文)」より
    • Peer Reviewed
  • [Journal Article] Insulin as a T cell antigen in type 1 diabetes supported by the evidence from the insulin knockout NOD mice.2007

    • Author(s)
      Moriyama H, et. al.
    • Journal Title

      Diabetes Res Clin Pract.

      Pages: S155-160

    • Description
      「研究成果報告書概要(和文)」より
    • Peer Reviewed
  • [Journal Article] Immunological aspects of `fulminant type 1 diabetes'2007

    • Author(s)
      Nagata, M, H. Moriyama, R. Kotani, H. Yasuda, M. Kishi, M. Kurohara, K. Hara, K. Yokono
    • Journal Title

      Diabetes Res Clin Pract S99-S103

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Modification of the Rb-binding Domain of Replication-Competent Adenovirus Vector Enhances Cytotoxicity Against Human Esophageal Cancers via NF-kB Activity2007

    • Author(s)
      Yamada, K, Moriyama, H, Yasuda, H, Hara, K, Maniwa, Y, Hamada, H, Koichi, Yokono, Nagata, M
    • Journal Title

      Hum Gene Ther 18(5)

      Pages: 389-400

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Insulin as a T cell antigen in type 1 diabetes supported by the evidence from the insulin knockout NOD mice2007

    • Author(s)
      Moriyama, H., Nagata, M., T., Arai, Y., Okumachi, K., Yamada, R., Kotani, H., Yasuda, K., Hata, K, Yokono
    • Journal Title

      Diabetes Res Clin Pract S155-160

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Low-dose warfarin functions as an immunomodulator to prevent cyclophosphamide-induced NOD diabetes

    • Author(s)
      Kurohara, M, Yasuda, H, Moriyama, H, Sakata, M, Yamada, K, Kotani, R, Nakayama, M, Hara, K, Yokono, K, Nagata, M
    • Journal Title

      Kobe J. Med. Sci (in press)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Presentation] Preventive effect of NOD^<LPR/LPR_>derived dendritic cells to autoimmune diabetes via fas-fasL interaction.2007

    • Author(s)
      Kishi M.
    • Organizer
      9th International Congress of the Immunology of Diabetes Society and American Diabetes Association Research Symposium
    • Place of Presentation
      Miami USA
    • Year and Date
      20071214-18
    • Description
      「研究成果報告書概要(和文)」より
  • [Presentation] TGF-β1-Modelated Dendritic Cells Inducing High CDld Expression Result in Prevention of Autoimmune Diabetes In NOD Mice2006

    • Author(s)
      Yasuda H.
    • Organizer
      66th Scientific Sessions of American Diabetes Association
    • Place of Presentation
      Washington, DC USA
    • Year and Date
      20060609-13
    • Description
      「研究成果報告書概要(和文)」より
  • [Presentation] Pioglitazone投与によるNODマウスの糖尿病発症制御2006

    • Author(s)
      黒原みどり
    • Organizer
      第49回日本糖尿病学会年次学術集会・総会
    • Place of Presentation
      東京
    • Year and Date
      20060525-27
    • Description
      「研究成果報告書概要(和文)」より

URL: 

Published: 2010-02-04  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi